AI Tokens
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Analysis of Income Taxes

Microsoft Excel

Income Tax Expense (Benefit)

Biogen Inc., income tax expense (benefit), continuing operations

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Federal 319,100 647,000 947,400 1,131,800 2,201,400
State 23,100 41,200 59,100 45,500 57,000
Foreign 137,100 155,100 84,400 140,000 108,600
Current 479,300 843,300 1,090,900 1,317,300 2,367,000
Federal (242,500) (1,749,900) 1,143,900 (62,000) 241,000
State (11,900) (6,800) (2,300) (7,400) 9,900
Foreign (172,400) 1,905,700 (1,074,500) 177,700 (159,200)
Deferred (426,800) 149,000 67,100 108,300 91,700
Income tax expense 52,500 992,300 1,158,000 1,425,600 2,458,700

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The total income tax expense exhibits a consistent and significant downward trajectory over the five-year period from 2017 to 2021. The total tax burden decreased from 2,458,700 thousand US dollars in 2017 to 52,500 thousand US dollars by the end of 2021, representing a substantial reduction in overall tax liability.

Current Income Tax Trends
A continuous decline is observed in current income tax expenses throughout the analyzed period. The amount dropped from 2,367,000 thousand US dollars in 2017 to 479,300 thousand US dollars in 2021. This steady year-over-year decrease suggests a persistent reduction in taxable income or the application of more favorable current tax conditions.
Deferred Income Tax Volatility
Deferred tax components remained relatively low and stable between 2017 and 2020, fluctuating between 67,100 and 149,000 thousand US dollars. However, a sharp reversal occurred in 2021, where the deferred tax transitioned to a benefit of 426,800 thousand US dollars. This shift significantly offset the current tax expense for that year.
Total Tax Expense Synthesis
The collapse in the total income tax expense is primarily driven by the sustained decrease in current taxes, further accelerated in 2021 by the recognized deferred tax benefit. By 2021, the total tax expense of 52,500 thousand US dollars reached its lowest point in the period, reflecting a near-total erosion of the tax expense compared to the 2017 baseline.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Effective Income Tax Rate (EITR)

Biogen Inc., effective income tax rate (EITR) reconciliation

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
U.S. federal statutory tax rate 21.00% 21.00% 21.00% 21.00% 35.00%
State taxes 0.80% 0.70% 0.80% 0.60% 0.80%
Taxes on foreign earnings -10.50% -3.30% -4.50% -1.90% -11.10%
Tax credits -3.80% -1.20% -1.10% -0.90% -0.80%
Purchased intangible assets -1.60% 0.70% 0.40% 1.20% 1.40%
Divestiture of Denmark manufacturing operations 0.00% -0.40% 1.00% 0.00% 0.00%
Internal reorganization of certain intellectual property rights 0.00% 0.00% -2.10% 0.00% 0.00%
TECFIDERA impairment 0.00% 1.80% 0.00% 0.00% 0.00%
GILTI 1.30% 1.30% 1.50% 1.60% 0.00%
Other permanent items 0.00% 0.00% 0.20% 0.30% 0.70%
Swiss tax reform 0.00% 0.00% -0.80% 0.00% 0.00%
Neurimmune tax impacts -5.30% -0.10% 0.00% 0.00% 0.00%
Manufacturing deduction 0.00% 0.00% 0.00% 0.00% -1.90%
Impairment of ZINBRYTA related tax assets 0.00% 0.00% 0.00% 0.00% 0.90%
Other 1.10% -0.80% -0.10% 0.20% 0.00%
Effective tax rate, before U.S. tax reform 3.00% 19.70% 16.30% 22.10% 25.00%
U.S. tax reform 0.00% 0.00% 0.00% 2.10% 22.90%
Effective tax rate 3.00% 19.70% 16.30% 24.20% 47.90%

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The effective income tax rate exhibited a significant overall decline over the five-year period, falling from a peak of 47.90% in 2017 to 3.00% by 2021. This trajectory was characterized by a sharp initial reduction following the transition from a 35.00% federal statutory tax rate to 21.00%. While the rate showed relative stability between 16.30% and 24.20% from 2018 through 2020, a substantial contraction occurred in 2021, resulting in a near-minimal tax burden relative to earnings.

Impact of U.S. Tax Reform
The effective tax rate in 2017 was heavily skewed by U.S. tax reform, which added 22.90% to the rate, offsetting the statutory reduction. A smaller residual impact of 2.10% persisted into 2018. Following this period, the baseline shifted to the lower 21.00% statutory rate, facilitating a lower effective tax floor.
Foreign Earnings and Tax Credits
Taxes on foreign earnings and tax credits served as consistent downward pressures on the effective tax rate. The reductive effect of foreign earnings taxes was particularly pronounced in 2017 (-11.10%) and 2021 (-10.50%). Tax credits also showed an accelerating trend of reduction, moving from -0.80% in 2017 to -3.80% in 2021.
Event-Driven Tax Adjustments
Several non-recurring items influenced the annual rates. The 2021 rate was significantly lowered by Neurimmune tax impacts of -5.30%. Earlier fluctuations included a -2.10% reduction from the internal reorganization of intellectual property rights in 2019 and a 1.80% increase linked to the TECFIDERA impairment in 2020.
Global Intangible Low-Taxed Income (GILTI)
Beginning in 2018, GILTI introduced a consistent additive component to the tax rate, contributing between 1.30% and 1.60% annually. This represents a permanent tax increase that partially offset the reductions gained from foreign earnings and credits.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Components of Deferred Tax Assets and Liabilities

Biogen Inc., components of deferred tax assets and liabilities

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Tax credits 121,000 113,400 106,600 102,800 60,000
Inventory, other reserves, and accruals 199,400 165,900 162,000 163,900 147,800
Intangibles, net 1,477,500 1,546,000 3,380,000 2,298,600 378,800
Neurimmune’s tax basis in ADUHELM 475,800 — — — —
Net operating loss 1,973,000 2,080,300 130,400 213,100 209,800
Share-based compensation 31,700 23,300 23,800 25,800 26,900
Other 208,800 103,100 103,700 38,900 25,100
Deferred tax assets, gross 4,487,200 4,032,000 3,906,500 2,843,100 848,400
Valuation allowance (1,961,300) (1,753,900) (1,100) (20,000) (16,600)
Deferred tax assets 2,525,900 2,278,100 3,905,400 2,823,100 831,800
Purchased intangible assets (256,600) (396,200) (350,300) (232,800) (250,700)
GILTI (1,037,600) (1,143,700) (1,381,600) (544,600) —
Tax credits (260,200) (174,600) (1,617,200) (1,425,700) —
Depreciation, amortization and other (250,900) (227,000) (135,000) (102,300) (107,900)
Deferred tax liabilities (1,805,300) (1,941,500) (3,484,100) (2,305,400) (358,600)
Deferred tax assets (liabilities), net 720,600 336,600 421,300 517,700 473,200

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The overall trajectory of deferred tax assets and liabilities reflects significant volatility between 2017 and 2021, characterized by a substantial expansion of gross assets offset by an increasing valuation allowance and fluctuating liability obligations.

Gross Deferred Tax Assets
Gross deferred tax assets experienced a consistent upward trend, rising from 848.4 million USD in 2017 to 4.49 billion USD by 2021. The most significant growth occurred between 2017 and 2019, primarily driven by a surge in intangibles, which peaked at 3.38 billion USD in 2019. A subsequent shift in the asset composition is observed in 2020 and 2021, where net operating losses became a dominant component, increasing from 130.4 million USD in 2019 to 1.97 billion USD in 2021. Additionally, the 2021 period saw the introduction of Neurimmune’s tax basis in ADUHELM, contributing 475.8 million USD to the asset base.
Valuation Allowance
A dramatic shift in the valuation allowance is evident starting in 2020. While the allowance remained negligible from 2017 through 2019, peaking at only 20 million USD in 2018, it escalated sharply to 1.75 billion USD in 2020 and further to 1.96 billion USD in 2021. This indicates a significant adjustment in the assessment of the realizability of the deferred tax assets, effectively reducing the net deferred tax assets despite the growth in gross figures.
Deferred Tax Liabilities
Deferred tax liabilities exhibited a peak in 2019 at 3.48 billion USD before trending downward to 1.81 billion USD by 2021. The primary drivers of this volatility were tax credits and GILTI (Global Intangible Low-Taxed Income). Tax credits as a liability peaked at 1.62 billion USD in 2019 but contracted sharply to 260.2 million USD by 2021. Similarly, GILTI liabilities peaked in 2019 at 1.38 billion USD and gradually declined to 1.04 billion USD by 2021.
Net Deferred Tax Position
The net deferred tax asset (liability) position remained positive throughout the five-year period, though it fluctuated. The net position reached a low of 336.6 million USD in 2020, largely due to the simultaneous spike in the valuation allowance and the persistence of deferred tax liabilities. However, by the end of 2021, the net position recovered to 720.6 million USD, reflecting a strengthened balance between the growing gross assets and the moderating liabilities.

In summary, the financial data indicates a transition from a liability-heavy profile in 2019 to a position more heavily influenced by valuation allowances and net operating losses by 2021. The marked increase in the valuation allowance suggests a more conservative approach to the recognition of future tax benefits.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Deferred Tax Assets and Liabilities, Classification

Biogen Inc., deferred tax assets and liabilities, classification

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Deferred tax asset 1,415,100 1,369,500 3,232,100 2,153,900 595,900
Deferred tax liability 694,500 1,032,800 2,810,800 1,636,200 122,600

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The deferred tax profile exhibits significant volatility between 2017 and 2021, characterized by a period of rapid expansion in both assets and liabilities followed by a substantial contraction.

Deferred Tax Assets
A sharp upward trajectory is observed from 2017 to 2019, with values increasing from 595.9 million to a peak of 3,232.1 million. This growth was followed by a significant reduction in 2020 to 1,369.5 million, remaining relatively stable with a marginal increase to 1,415.1 million by the end of 2021.
Deferred Tax Liabilities
A parallel pattern of expansion occurred between 2017 and 2019, where liabilities rose from 122.6 million to 2,810.8 million. Subsequently, a consistent downward trend emerged, with balances falling to 1,032.8 million in 2020 and further decreasing to 694.5 million in 2021.

The net deferred tax position remained consistently as a net asset throughout the analyzed period. While the gross balances peaked simultaneously in 2019, the net asset position experienced its most significant expansion in 2021, reaching 720.6 million, as the reduction in deferred tax liabilities outpaced the stabilization of deferred tax assets.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Financial Statements: Removal of Deferred Taxes

Biogen Inc., Financial Data: Reported vs. Adjusted

Biogen Inc., adjustments to financial statements

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Adjustment to Total Assets
Total assets (as reported) 23,877,300 24,618,900 27,234,300 25,288,900 23,652,600
Less: Noncurrent deferred tax assets, net 1,415,100 1,369,500 3,232,100 2,153,900 595,900
Total assets (adjusted) 22,462,200 23,249,400 24,002,200 23,135,000 23,056,700
Adjustment to Total Liabilities
Total liabilities (as reported) 12,917,600 13,932,800 13,895,200 12,257,300 11,054,500
Less: Noncurrent deferred tax liabilities, net 694,500 1,032,800 2,810,800 1,636,200 122,600
Total liabilities (adjusted) 12,223,100 12,900,000 11,084,400 10,621,100 10,931,900
Adjustment to Total Biogen Inc. Shareholders’ Equity
Total Biogen Inc. shareholders’ equity (as reported) 10,896,200 10,700,300 13,343,200 13,039,600 12,612,800
Less: Net deferred tax assets (liabilities) 720,600 336,600 421,300 517,700 473,200
Total Biogen Inc. shareholders’ equity (adjusted) 10,175,600 10,363,700 12,921,900 12,521,900 12,139,600
Adjustment to Net Income Attributable To Biogen Inc.
Net income attributable to Biogen Inc. (as reported) 1,556,100 4,000,600 5,888,500 4,430,700 2,539,100
Add: Deferred income tax expense (benefit) (426,800) 149,000 67,100 108,300 91,700
Net income attributable to Biogen Inc. (adjusted) 1,129,300 4,149,600 5,955,600 4,539,000 2,630,800

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The removal of deferred taxes from the financial statements reveals a distinct divergence between reported and adjusted financial positions from 2017 through 2021. This adjustment process highlights the impact of deferred tax assets and liabilities on the company's reported solvency and profitability metrics.

Asset Valuation Trends
Reported total assets exhibited an upward trend from 2017 to a peak of 27.23 billion US$ in 2019, followed by a decline to 23.88 billion US$ by 2021. The adjusted total assets remained consistently lower than the reported figures, with the widest variance occurring in 2019. This gap suggests a significant concentration of deferred tax assets during the 2018-2019 period, which reduced the adjusted asset base relative to the reported base.
Liability Structure Analysis
Reported total liabilities increased steadily from 11.05 billion US$ in 2017 to a peak of 13.93 billion US$ in 2020. The adjusted total liabilities show significant volatility in the removal of deferred tax liabilities, particularly in 2019, where reported liabilities exceeded adjusted liabilities by approximately 2.81 billion US$. By 2020, the difference narrowed substantially, indicating a significant reversal or settlement of deferred tax obligations.
Shareholders' Equity Impact
Reported shareholders' equity grew until 2019, reaching 13.34 billion US$, before experiencing a sharp contraction to 10.70 billion US$ in 2020. Adjusted equity followed a similar trajectory but remained lower than reported equity throughout the period. The variance between reported and adjusted equity remained relatively stable compared to the volatility seen in total assets and liabilities, though the gap widened in 2021 to approximately 720 million US$.
Net Income Adjustments
Reported net income peaked in 2019 at 5.89 billion US$ before declining sharply to 1.56 billion US$ in 2021. Between 2017 and 2020, adjusted net income was consistently higher than reported net income, suggesting that deferred tax expenses were weighing down reported earnings. However, this pattern reversed in 2021, where adjusted net income fell to 1.13 billion US$, significantly below the reported 1.56 billion US$, indicating that the reported net income for that year was bolstered by tax-related adjustments.

Overall, the adjustment for deferred taxes reveals that the company's reported financial health was heavily influenced by tax accounting volatility, particularly in 2019. The transition from 2020 to 2021 shows a shift where tax adjustments began to negatively impact the adjusted net income relative to the reported figures.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

Biogen Inc., Financial Ratios: Reported vs. Adjusted

Biogen Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net Profit Margin
Reported net profit margin 14.17% 29.76% 40.96% 32.93% 20.69%
Adjusted net profit margin 10.28% 30.86% 41.42% 33.74% 21.43%
Total Asset Turnover
Reported total asset turnover 0.46 0.55 0.53 0.53 0.52
Adjusted total asset turnover 0.49 0.58 0.60 0.58 0.53
Financial Leverage
Reported financial leverage 2.19 2.30 2.04 1.94 1.88
Adjusted financial leverage 2.21 2.24 1.86 1.85 1.90
Return on Equity (ROE)
Reported ROE 14.28% 37.39% 44.13% 33.98% 20.13%
Adjusted ROE 11.10% 40.04% 46.09% 36.25% 21.67%
Return on Assets (ROA)
Reported ROA 6.52% 16.25% 21.62% 17.52% 10.73%
Adjusted ROA 5.03% 17.85% 24.81% 19.62% 11.41%

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The financial performance from 2017 to 2021 is characterized by a period of significant growth in profitability and efficiency that peaked in 2019, followed by a notable contraction through 2021. The removal of deferred taxes generally resulted in higher adjusted ratios for the majority of the period, although this trend reversed for several key metrics in the final year.

Profitability Analysis
Reported net profit margins experienced a steady ascent from 20.69% in 2017 to a peak of 40.96% in 2019, before declining sharply to 14.17% by 2021. The adjusted net profit margin followed a similar trajectory, reaching a higher peak of 41.42% in 2019. A significant divergence occurred in 2021, where the adjusted margin of 10.28% fell below the reported margin, suggesting that deferred tax adjustments became a drag on profitability in the final year.
Asset Efficiency
Total asset turnover remained relatively stable between 2017 and 2020, with reported ratios ranging from 0.52 to 0.55. Adjusted total asset turnover consistently exceeded reported figures throughout the entire five-year period, peaking at 0.60 in 2019. A downward trend is evident in 2021, with the reported turnover dropping to 0.46 and the adjusted turnover to 0.49.
Financial Leverage
Financial leverage trended upward from 2017, with the reported ratio increasing from 1.88 to a peak of 2.30 in 2020. Adjusted financial leverage exhibited more volatility; it decreased slightly between 2017 and 2019 before rising to 2.24 in 2020. By 2021, both reported and adjusted leverage converged near the 2.20 level.
Return on Investment (ROE and ROA)
Return on Equity (ROE) and Return on Assets (ROA) mirrored the volatility of the profit margins. Reported ROE peaked at 44.13% in 2019 and decreased to 14.28% by 2021, while reported ROA peaked at 21.62% in 2019 and fell to 6.52% in 2021. From 2017 to 2020, the adjusted figures for both ROE and ROA were consistently higher than the reported values. However, in 2021, the adjusted ROE (11.10%) and adjusted ROA (5.03%) both fell below their reported counterparts, indicating a shift in the impact of deferred tax accounting on shareholder and asset returns.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Selected Financial Data (US$ in thousands)
Net income attributable to Biogen Inc. 1,556,100 4,000,600 5,888,500 4,430,700 2,539,100
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Profitability Ratio
Net profit margin1 14.17% 29.76% 40.96% 32.93% 20.69%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in thousands)
Adjusted net income attributable to Biogen Inc. 1,129,300 4,149,600 5,955,600 4,539,000 2,630,800
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Profitability Ratio
Adjusted net profit margin2 10.28% 30.86% 41.42% 33.74% 21.43%

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

2021 Calculations

1 Net profit margin = 100 × Net income attributable to Biogen Inc. ÷ Revenue
= 100 × 1,556,100 ÷ 10,981,700 = 14.17%

2 Adjusted net profit margin = 100 × Adjusted net income attributable to Biogen Inc. ÷ Revenue
= 100 × 1,129,300 ÷ 10,981,700 = 10.28%


The financial performance from 2017 to 2021 exhibits a bell-shaped trajectory, with profitability peaking in 2019 followed by a significant contraction through 2021. Both reported and adjusted metrics follow this general path, although the decline in the final two years is notably severe.

Net Income Trends
Reported net income grew steadily from US$ 2,539.1 million in 2017 to a peak of US$ 5,888.5 million in 2019. A subsequent downturn occurred, with income falling to US$ 4,000.6 million in 2020 and further decreasing to US$ 1,556.1 million in 2021.
Net Profit Margin Analysis
The adjusted net profit margin mirrored the income trend, rising from 21.43% in 2017 to a peak of 41.42% in 2019. Following this peak, the margin compressed to 30.86% in 2020 and experienced a sharp decline to 10.28% in 2021, marking the lowest level of profitability across the five-year period.
Comparative Variance between Reported and Adjusted Figures
From 2017 through 2020, adjusted net income and profit margins consistently remained higher than their reported counterparts, indicating that non-recurring expenses or specific accounting charges were negatively impacting reported results. However, this trend inverted in 2021, where reported net income of US$ 1,556.1 million exceeded adjusted net income of US$ 1,129.3 million, and the reported profit margin of 14.17% surpassed the adjusted margin of 10.28%.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Selected Financial Data (US$ in thousands)
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Total assets 23,877,300 24,618,900 27,234,300 25,288,900 23,652,600
Activity Ratio
Total asset turnover1 0.46 0.55 0.53 0.53 0.52
Adjusted for Deferred Taxes
Selected Financial Data (US$ in thousands)
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Adjusted total assets 22,462,200 23,249,400 24,002,200 23,135,000 23,056,700
Activity Ratio
Adjusted total asset turnover2 0.49 0.58 0.60 0.58 0.53

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

2021 Calculations

1 Total asset turnover = Revenue ÷ Total assets
= 10,981,700 ÷ 23,877,300 = 0.46

2 Adjusted total asset turnover = Revenue ÷ Adjusted total assets
= 10,981,700 ÷ 22,462,200 = 0.49


The analysis of asset utilization from 2017 to 2021 reveals a period of expansion in the asset base followed by a contraction, coinciding with a peak and subsequent decline in operational efficiency. Total assets, both reported and adjusted, reached their highest levels in 2019 before trending downward through 2021.

Total Asset Base Trends
Reported total assets increased from 23,652,600 thousand US$ in 2017 to a peak of 27,234,300 thousand US$ in 2019, representing a growth of approximately 15%. However, a reversal occurred after 2019, with assets declining to 23,877,300 thousand US$ by 2021. Adjusted total assets exhibited lower volatility, peaking at 24,002,200 thousand US$ in 2019 and ending the period at 22,462,200 thousand US$.
Adjusted Total Asset Turnover Performance
The adjusted total asset turnover ratio shows a progressive increase from 0.53 in 2017 to a peak of 0.60 in 2019, indicating improved efficiency in generating revenue from adjusted assets. This upward trend reversed after 2019, with the ratio falling to 0.58 in 2020 and dropping more sharply to 0.49 by the end of 2021.
Comparative Analysis of Reported vs. Adjusted Metrics
A consistent variance is observed between reported and adjusted turnover ratios, with the adjusted figures remaining higher throughout the entire five-year period. While the reported asset turnover remained relatively stagnant between 2017 and 2019 (0.52 to 0.53), the adjusted ratio grew more significantly (0.53 to 0.60), suggesting that the adjustments remove factors that otherwise obscure operational efficiency. Both metrics converged toward a downward trend in 2021, where reported turnover fell to 0.46 and adjusted turnover fell to 0.49.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Selected Financial Data (US$ in thousands)
Total assets 23,877,300 24,618,900 27,234,300 25,288,900 23,652,600
Total Biogen Inc. shareholders’ equity 10,896,200 10,700,300 13,343,200 13,039,600 12,612,800
Solvency Ratio
Financial leverage1 2.19 2.30 2.04 1.94 1.88
Adjusted for Deferred Taxes
Selected Financial Data (US$ in thousands)
Adjusted total assets 22,462,200 23,249,400 24,002,200 23,135,000 23,056,700
Adjusted total Biogen Inc. shareholders’ equity 10,175,600 10,363,700 12,921,900 12,521,900 12,139,600
Solvency Ratio
Adjusted financial leverage2 2.21 2.24 1.86 1.85 1.90

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

2021 Calculations

1 Financial leverage = Total assets ÷ Total Biogen Inc. shareholders’ equity
= 23,877,300 ÷ 10,896,200 = 2.19

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Biogen Inc. shareholders’ equity
= 22,462,200 ÷ 10,175,600 = 2.21


The financial position from 2017 to 2021 is characterized by an initial growth phase in assets and equity followed by a contraction and an increase in financial leverage. Total reported assets reached a peak of US$ 27.23 billion in 2019 before declining to US$ 23.88 billion by the end of 2021. Shareholders' equity followed a similar trajectory, peaking in 2019 at US$ 13.34 billion and experiencing a significant reduction in 2020 to US$ 10.70 billion.

Asset and Equity Adjustments
Adjusted values for both total assets and shareholders' equity were consistently lower than the reported figures throughout the analyzed period. For instance, in 2021, adjusted total assets were US$ 22.46 billion compared to the reported US$ 23.88 billion, and adjusted shareholders' equity was US$ 10.18 billion compared to the reported US$ 10.90 billion. This persistent gap indicates that the adjustments applied to the financial statements consistently reduced the recognized capital base.
Reported Financial Leverage Trends
Reported financial leverage demonstrated a steady upward trend for the majority of the period, rising from 1.88 in 2017 to a peak of 2.30 in 2020. A slight correction occurred in 2021, with the ratio decreasing to 2.19, though it remained significantly higher than the 2017 levels.
Adjusted Financial Leverage Trends
Adjusted financial leverage exhibited a different pattern than the reported ratio between 2017 and 2019, remaining relatively stable with values between 1.85 and 1.90. However, a sharp increase was observed in 2020, where the ratio climbed to 2.24, and it remained elevated at 2.21 in 2021. This shift suggests that the factors driving the increase in leverage starting in 2020 were not offset by the adjustments that had previously stabilized the ratio in earlier years.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Selected Financial Data (US$ in thousands)
Net income attributable to Biogen Inc. 1,556,100 4,000,600 5,888,500 4,430,700 2,539,100
Total Biogen Inc. shareholders’ equity 10,896,200 10,700,300 13,343,200 13,039,600 12,612,800
Profitability Ratio
ROE1 14.28% 37.39% 44.13% 33.98% 20.13%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in thousands)
Adjusted net income attributable to Biogen Inc. 1,129,300 4,149,600 5,955,600 4,539,000 2,630,800
Adjusted total Biogen Inc. shareholders’ equity 10,175,600 10,363,700 12,921,900 12,521,900 12,139,600
Profitability Ratio
Adjusted ROE2 11.10% 40.04% 46.09% 36.25% 21.67%

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

2021 Calculations

1 ROE = 100 × Net income attributable to Biogen Inc. ÷ Total Biogen Inc. shareholders’ equity
= 100 × 1,556,100 ÷ 10,896,200 = 14.28%

2 Adjusted ROE = 100 × Adjusted net income attributable to Biogen Inc. ÷ Adjusted total Biogen Inc. shareholders’ equity
= 100 × 1,129,300 ÷ 10,175,600 = 11.10%


Between 2017 and 2021, profitability and equity efficiency experienced a period of significant growth followed by a sharp contraction. The financial performance peaked in 2019 across all primary return metrics before entering a downward trend that accelerated in 2021.

Net Income Trends
Both reported and adjusted net income exhibited an upward trajectory from 2017 to 2019. Reported net income increased from 2,539,100 thousand US$ in 2017 to a peak of 5,888,500 thousand US$ in 2019. Adjusted net income followed a similar pattern, reaching its highest point of 5,955,600 thousand US$ in 2019. A reversal occurred in 2020, with a subsequent steep decline in 2021, where adjusted net income fell to 1,129,300 thousand US$, marking a significant reduction from the 2019 peak.
Shareholders' Equity Evolution
Total shareholders' equity remained relatively stable with slight growth between 2017 and 2019, peaking at 13,343,200 thousand US$ (Reported). A notable decrease was observed in 2020, with reported equity dropping to 10,700,300 thousand US$. Adjusted equity followed this downward shift, declining from 12,921,900 thousand US$ in 2019 to 10,175,600 thousand US$ by 2021.
Adjusted Return on Equity (ROE) Analysis
The Adjusted ROE demonstrated a strong expansion phase, rising from 21.67% in 2017 to a maximum of 46.09% in 2019. While the metric remained robust at 40.04% in 2020, it suffered a severe contraction in 2021, falling to 11.10%. This represents the lowest ROE in the analyzed five-year period, indicating a substantial decrease in the efficiency of generating profits from shareholders' equity.
Comparative Performance of Reported vs. Adjusted Metrics
Throughout most of the period from 2017 to 2020, Adjusted ROE consistently exceeded Reported ROE, suggesting that adjustments for non-recurring or non-cash items presented a more favorable view of operational efficiency. However, in 2021, this trend reversed, as Reported ROE (14.28%) surpassed Adjusted ROE (11.10%), reflecting a shift in the underlying components affecting the net income calculations.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Selected Financial Data (US$ in thousands)
Net income attributable to Biogen Inc. 1,556,100 4,000,600 5,888,500 4,430,700 2,539,100
Total assets 23,877,300 24,618,900 27,234,300 25,288,900 23,652,600
Profitability Ratio
ROA1 6.52% 16.25% 21.62% 17.52% 10.73%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in thousands)
Adjusted net income attributable to Biogen Inc. 1,129,300 4,149,600 5,955,600 4,539,000 2,630,800
Adjusted total assets 22,462,200 23,249,400 24,002,200 23,135,000 23,056,700
Profitability Ratio
Adjusted ROA2 5.03% 17.85% 24.81% 19.62% 11.41%

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

2021 Calculations

1 ROA = 100 × Net income attributable to Biogen Inc. ÷ Total assets
= 100 × 1,556,100 ÷ 23,877,300 = 6.52%

2 Adjusted ROA = 100 × Adjusted net income attributable to Biogen Inc. ÷ Adjusted total assets
= 100 × 1,129,300 ÷ 22,462,200 = 5.03%


The financial performance from 2017 to 2021 is characterized by a period of significant growth in profitability and asset efficiency peaking in 2019, followed by a sharp decline through 2021. A consistent divergence exists between reported and adjusted figures, suggesting the impact of non-recurring items or specific accounting adjustments on the bottom line.

Net Income Trends
Reported net income grew steadily from 2,539,100 thousand US$ in 2017 to a peak of 5,888,500 thousand US$ in 2019. However, a downward trajectory followed, with a substantial decrease to 1,556,100 thousand US$ by 2021. Adjusted net income followed a similar pattern, peaking at 5,955,600 thousand US$ in 2019 before dropping to 1,129,300 thousand US$ in 2021. Notably, while adjusted net income exceeded reported net income from 2017 to 2020, this trend reversed in 2021, where adjusted net income fell significantly below the reported figure.
Asset Base Utilization
Reported total assets increased from 23,652,600 thousand US$ in 2017 to 27,234,300 thousand US$ in 2019, before contracting to 23,877,300 thousand US$ in 2021. Adjusted total assets remained more stable, fluctuating within a narrower range between 22,462,200 thousand US$ and 24,002,200 thousand US$. The convergence of reported and adjusted assets toward the end of the period indicates a reduction in the adjustments applied to the balance sheet.
Adjusted Return on Assets (ROA) Analysis
The Adjusted ROA exhibited a strong upward trend in the early part of the period, rising from 11.41% in 2017 to a peak of 24.81% in 2019, indicating highly efficient utilization of assets to generate adjusted earnings. A subsequent contraction occurred, with the ratio falling to 17.85% in 2020 and plummeting to 5.03% in 2021. This 2021 low represents the lowest efficiency level in the five-year period and marks a significant departure from the reported ROA of 6.52%, suggesting that adjusted earnings declined more steeply than reported earnings relative to the asset base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?